Search Page

1

Emergence of ERBB2 Mutation as a Biomarker and an Actionable Target in Solid Cancers.

Subramanian J, Katta A, Masood A, Vudem DR, Kancha RK. Subramanian J, et al. Among authors: Kancha RK. Oncologist. 2019 Dec;24(12):e1303-e1314. doi: 10.1634/theoncologist.2018-0845. Epub 2019 Jul 10. Oncologist. 2019. PMID: 31292270 Free PMC article. Review.

Cite

Share

2

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib.

Masood A, Kancha RK, Subramanian J. Masood A, et al. Among authors: Kancha RK. Semin Oncol. 2019 Jun;46(3):271-283. doi: 10.1053/j.seminoncol.2019.08.004. Epub 2019 Sep 11. Semin Oncol. 2019. PMID: 31558282 Free article. Review.

Cite

Share

3

Computational Analysis of Epidermal Growth Factor Receptor Mutations Predicts Differential Drug Sensitivity Profiles toward Kinase Inhibitors.

Akula S, Kamasani S, Sivan SK, Manga V, Vudem DR, Kancha RK. Akula S, et al. Among authors: Kancha RK. J Thorac Oncol. 2018 May;13(5):721-726. doi: 10.1016/j.jtho.2018.01.003. Epub 2018 Jan 31. J Thorac Oncol. 2018. PMID: 29369805 Free article.

Cite

Share

4

Synthesis of novel forskolin isoxazole derivatives with potent anti-cancer activity against breast cancer cell lines.

Burra S, Voora V, Rao CP, Vijay Kumar P, Kancha RK, David Krupadanam GL. Burra S, et al. Among authors: Kancha RK. Bioorg Med Chem Lett. 2017 Sep 15;27(18):4314-4318. doi: 10.1016/j.bmcl.2017.08.033. Epub 2017 Aug 16. Bioorg Med Chem Lett. 2017. PMID: 28838692

Cite

Share

5

FeCl₃ catalysed 7-membered ring formation in a single pot: a new route to indole-fused oxepines/azepines and their cytotoxic activity.

Shiva Kumar K, Siddi Ramulu M, Rajesham B, Kumar NP, Voora V, Kancha RK. Shiva Kumar K, et al. Among authors: Kancha RK. Org Biomol Chem. 2017 May 23;15(20):4468-4476. doi: 10.1039/c7ob00715a. Org Biomol Chem. 2017. PMID: 28497830

Cite

Share

6

Evolvement of nutraceutical onion plants engineered for resveratrol biosynthetic pathway.

Naini R, Pavankumar P, Prabhakar S, Kancha RK, Rao KV, Reddy VD. Naini R, et al. Among authors: Kancha RK. Plant Cell Rep. 2019 Sep;38(9):1127-1137. doi: 10.1007/s00299-019-02432-y. Epub 2019 Jun 1. Plant Cell Rep. 2019. PMID: 31154513

Cite

Share

7

Computational analysis of ABL kinase mutations allows predicting drug sensitivity against selective kinase inhibitors.

Kamasani S, Akula S, Sivan SK, Manga V, Duyster J, Vudem DR, Kancha RK. Kamasani S, et al. Among authors: Kancha RK. Tumour Biol. 2017 May;39(5):1010428317701643. doi: 10.1177/1010428317701643. Tumour Biol. 2017. PMID: 28475010

Cite

Share

8

Molecular docking analysis of imine stilbene analogs and evaluation of their anti-aging activity using yeast and mammalian cell models.

Naini R, Chikati R, Vudem DR, Kancha RK. Naini R, et al. Among authors: Kancha RK. J Recept Signal Transduct Res. 2019 Feb;39(1):55-59. doi: 10.1080/10799893.2019.1605529. Epub 2019 May 28. J Recept Signal Transduct Res. 2019. PMID: 31132911

Cite

Share

9

Targeting oncoprotein stability overcomes drug resistance caused by FLT3 kinase domain mutations.

Yu C, Kancha RK, Duyster J. Yu C, et al. Among authors: Kancha RK. PLoS One. 2014 May 21;9(5):e97116. doi: 10.1371/journal.pone.0097116. eCollection 2014. PLoS One. 2014. PMID: 24849514 Free PMC article.

Cite

Share

10

Elucidation of conformational diversity of druggable enzymes and classification of chemical modulators based on inhibitor-bound structures.

Akula S, Vanamamalai VK, Nair Ru VP, Vudem DR, Kancha RK. Akula S, et al. Among authors: Kancha RK. J Biomol Struct Dyn. 2019 Oct;37(17):4563-4568. doi: 10.1080/07391102.2018.1553740. Epub 2019 Jan 9. J Biomol Struct Dyn. 2019. PMID: 30488775

Cite

Share